Month: May 2023

TORONTO, May 15, 2023 (GLOBE NEWSWIRE) — Base Carbon Inc. (NEO: BCBN) (OTCQX: BCBNF) (“Base Carbon”, or the “Company”) is pleased to announce its first-quarter 2023 consolidated financial results. All financial references are denominated in U.S. dollars, unless otherwise noted. Financial Highlights for the First-Quarter ended March 31, 2023:As at March 31, 2023, the Company had total assets of $43.1 million, mainly comprising of:$8.6 million in cash and cash equivalents, $0.2 million in related party loan receivable, $0.4 million in prepaid and other assets, $27.5 million in investments in carbon credit projects, $1.4 million equity investment in ACX Holdings Ltd. (AirCarbon), and $4.9 million in investment in associate company Hardwick Climate Business Limited.As at March 31, 2023, the Company had $0.3 million in current...

Conference call will be held on Monday, May 15 at 10 AM ET VANCOUVER, British Columbia, May 15, 2023 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC (BABY) (BABYF) (0YL.F) (“Else” or the “Company”) the Plant-Based baby, toddler, and children nutrition company, today reported first quarter 2023 financial results for the period ending March 31, 2023. The financial statements and MD&A are available on SEDAR under the Company’s profile. First Quarter 2023 Financial Highlights1Q23 total revenues were $2.9M, an 82% increase versus $1.6M in 1Q22, and a 23% increase versus $2.3M in 4Q22. Revenue growth continued to be hampered by product shortages. While the company increased its production pace, the demand for its products also continued to grow, a combination that challenged available supply, especially...

Total revenues of $9.6 million for first quarter 2023, an increase of 23% over first quarter 2022, and consistent with 2023 revenue guidance Completed business combination with AMCI Acquisition Corp. II on February 8, 2023, raising $242 million of gross proceeds through the transaction Reaffirming full year 2023 revenue and adjusted EBITDA guidance CHICAGO, May 15, 2023 (GLOBE NEWSWIRE) —  LanzaTech Global, Inc. (Nasdaq: LNZA) (“LanzaTech” or the “Company”), a carbon recycling and leading Carbon Capture and Transformation (“CCT”) company, today reported its financial and operating results for the first quarter of 2023. In the first quarter, revenue totaled $9.6 million, an increase of 23% compared to $7.9 million in the first quarter of 2022. This strong revenue growth reflected continued growth across the business and was driven...

Lerøy Seafood Group ASA will present its results for Q1 2023 on 16 May 2023 at Høyres Hus (meeting room “Emil Stang”) in Oslo at 08:00 CET. The presentation will be held in Norwegian followed by a Q&A session. Delicious seafood will be served from 07:45 CET. You may alternatively follow the Norwegian presentation and submit questions through a live broadcast available on https://www.leroyseafood.com/no/investor/ . The quarterly report and presentation will be published at 06:30 CET. A recording of the presentation in English will be available from 12:00 CET on http://www.leroyseafood.com/en/investor . This information is subject to the disclosure requirements pursuant to Section5-12 the Norwegian Securities Trading Act.

― Appointed Alex C. Sapir CEO & President, effective July 1st, 2023 ― ― On track to complete enrollment in Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) during 2H’23 ― ― Active discussions continue with the U.S. Food and Drug Administration (FDA) to resolve clinical hold for FTX-6058 in sickle cell disease (SCD) ―  ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today reported financial results for the first quarter 2023 and provided a business update. “With today’s announcement of Alex as our next CEO and President, Fulcrum has ended the...

heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical Trial Initiation Expected in the First Half of 2024 VERVE-201 Targeting ANGPTL3 Progressing with Clinical Trial Initiation Expected in the Second Half of 2024 Well-capitalized with $508.7 Million Supporting Runway into the Second Half of 2025 BOSTON, May 15, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline progress and financial results for the first quarter of 2023. “The focus at Verve is to develop life-changing medicines for people with cardiovascular disease,” said...

Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”); Results from Part 2 Expected in Third Quarter of 2023 Second and Final Closing of PIPE Investment Completed, Raising Total Gross Proceeds of $7.5 million; Cash Runway into the Third Quarter of 2024  Jason M. Marks and Michael E. Dambach Appointed to Board of Directors Company Will Host a Conference Call and Webcast Today at 8:00 am ET  CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 15, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the first quarter ended March 31, 2023. “Based...

TORONTO, May 15, 2023 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2023. First Quarter 2023 Summary & Recent Highlights:Company continues to execute against Transformational PlanTotal revenue of $20.5 million, down $5.9 million, or 22%, year-over-year Cash system revenue represented approximately 66% of total systems and subscriptions revenue, compared to 53% in the prior year period Operating expenses of $21.9M, including approximately $0.9 million of costs related to restructuring activities, down $3.3M or 13% year-over-year Cash used in operations down 53% year-over-year GAAP net loss attributable to stockholders of $9.7 million, compared to GAAP net loss attributable...